EMERYVILLE, Calif. — Profluent, a company developing frontier AI models for protein design, has raised $106 million in new financing co-led by Altimeter Capital and Bezos Expeditions, bringing its total funding to $150 million. Existing investors—including Spark Capital, Insight Partners, and Air Street Capital—also participated. The new capital will accelerate Profluent’s mission to make biology programmable by designing next-generation genome editors, antibodies, enzymes, and other biologics for use across therapeutics, diagnostics, agriculture, and biomanufacturing.
Profluent is known for pioneering large-scale AI models that generate functional proteins. The company was the first to show that large language models can create working proteins (Nature Biotechnology, 2023), the first to design a CRISPR system entirely from scratch using AI (Nature, 2025), and among the first to demonstrate that AI scaling laws apply to protein design (NeurIPS, 2025). Profluent now maintains the world’s largest protein resource—its Protein Atlas—containing more than 115 billion unique AI-designed proteins.
The company’s foundation models and engineered proteins are already being used across the biotech and pharmaceutical sectors. OpenCRISPR-1, Profluent’s open-source gene editor, is now used by thousands of researchers, commercial labs, and major global biopharma companies. Profluent also has commercial partnerships with organizations including Revvity, Corteva Agriscience, The Rett Syndrome Research Trust, and Integrated DNA Technologies, Inc. As the scale of its models grows, so does the available design space—expanding the number of commercially valuable protein products that can be created.
“With this funding, we are accelerating the path from lab breakthroughs to real-world applications, creating bespoke proteins to solve challenges in human health and the environment,” said Ali Madani, Ph.D., founder and CEO of Profluent. “Partners are already deploying our technology while our R&D efforts are rapidly expanding the range and depth of our design capabilities. This capital enables Profluent to expand our platform’s capabilities, expand markets, and bring abundance to therapeutics, agriculture, and biomanufacturing.”
Profluent has broadened its commercial focus beyond genome editors to include antibodies, antigens, enzymes, and other biologic formats. The strong performance of its genome editing programs has de-risked the platform as it works toward delivering the first AI-designed therapeutic into human trials.
“Profluent combines world-class AI, biology, and therapeutic development expertise against the backdrop of thriving scaling laws,” said Jamin Ball, partner at Altimeter Capital. “This positions them not just as a frontier science company, but as the foundation of a massive new industry. Programmable biology opens the largest design space in nature and reaches into multi-trillion-dollar markets, and Profluent is only at the beginning of exploring it.”
